Inositol for Fatty Liver Disease

Current Guideline-Based Management

The American Association for the Study of Liver Diseases, European Association for the Study of the Liver, and Korean Association for the Study of the Liver recommend lifestyle modification as the cornerstone of NAFLD treatment, which includes a target 7-10% total body weight loss through caloric restriction to achieve meaningful improvements in liver inflammation and fibrosis 1, 2
The American College of Cardiology and other major guidelines suggest implementing a Mediterranean diet as the primary dietary approach, which reduces liver fat even without weight loss 1, 2
The American Heart Association recommends engaging in 150-300 minutes of moderate-intensity aerobic exercise weekly or 75-150 minutes of vigorous-intensity exercise 1, 2
Established pharmacologic options are reserved for biopsy-proven NASH with significant fibrosis and include vitamin E (800 IU/day) for non-diabetic patients and pioglitazone (30 mg/day) for patients with or without diabetes 1, 2

A 2020 systematic review found that inositol deficiency in animal models was associated with increased fatty liver, and supplementation reduced hepatic triglycerides and cholesterol accumulation in animal models 3, 4, 5, 6, 7
The American Association for the Study of Liver Diseases notes that major guidelines do not mention inositol as a recommended treatment for NAFLD 3, 4, 5, 1, 2

The American College of Cardiology suggests that lifestyle modifications, including 7-10% weight loss, Mediterranean diet, and 150-300 minutes weekly exercise, should be implemented as first-line therapy for NAFLD patients 1, 2
The American Diabetes Association recommends treating metabolic comorbidities aggressively, including diabetes, dyslipidemia, and hypertension 1, 2
The American Heart Association advises using statins for dyslipidemia despite liver disease, as they are safe 2

The American Association for the Study of Liver Diseases states that metformin is not recommended as a specific treatment for NAFLD, as it has no significant effect on liver histology 8, 7, 9, 2
The American College of Cardiology warns that rapid weight loss (>1 kg/week) may worsen portal inflammation and fibrosis 2
The American Heart Association notes that cardiovascular disease is the main driver of morbidity and mortality in NAFLD patients before cirrhosis develops, making aggressive management of metabolic comorbidities paramount 1